Trial
NCT02438761
PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Institut Curie
Collaborators
Fondation ARC; National Cancer Institute, France
Condition
Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome
Intervention
PF-05212384
Why stopped
No objective response was observed at the first step. The treatment was considered ineffective, with a complete clinical trial suspension.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-08